Release – ACCO Brands Corporation Announces Participation in Noble Capital Markets Virtual Road Show Series


ACCO Brands Corporation Announces Participation in Noble Capital Markets’ Virtual Road Show Series

 

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that its management will participate in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek. The virtual road show will feature a presentation from Boris Elisman, ACCO Brands Chairman and Chief Executive Officer, followed by a Q&A session proctored by Noble Senior Research Analyst Joe Gomes, featuring questions submitted by the audience.

The live broadcast of the virtual road show is scheduled for June 29, 2021, at 1 p.m. EDT. Registration is free and open to all investors. Register Here. The presentation also will be accessible through the Investor Relations section of www.accobrands.com or through Channelchek.com and will be archived on both websites following the event.

About ACCO Brands Corporation

ACCO Brands Corporation (NYSE: ACCO) is one of the world’s largest designers, marketers and manufacturers of branded academic, consumer and business products. Our widely recognized brands include Artline®, AT-A-GLANCE®, Barrilito®, Derwent®, Esselte®, Five Star®, Foroni®, GBC®, Hilroy®, Kensington®, Leitz®, Mead®, Quartet®, PowerA®, Rapid®, Rexel®, Swingline®, Tilibra®, Wilson Jones® and many others. Our products are sold in more than 100 countries around the world. More information about ACCO Brands, the Home of Great Brands Built by Great People, can be found at www.accobrands.com.

Christine Hanneman
Investor Relations
(847) 796-4320

Julie McEwan
Media Relations
(937) 974-8162

Source: ACCO Brands Corporation

Release – Kratos Awarded $8.6 Million Task Order to Complete 50shp Class Recuperated Turbine Engine for Future Group 3 UAVs


Kratos Awarded $8.6 Million Task Order to Complete 50shp Class Recuperated Turbine Engine for Future Group 3 UAVs

 

SAN DIEGO
June 24, 2021 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that Kratos Turbine Technologies (KTT) Division has been awarded an 
$8.6 million task order under its Advanced Turbine Technologies for 
Affordable Mission (ATTAM) ID/IQ contract. The program will be managed by the Turbine Engine Division of the 
Air Force Research Laboratory (AFRL/RQT). Under the contract KTT will complete the design, build, assemble and test of an affordable turboshaft engine for Group 3 UAVs. The engine design is convertible to produce the electrical power required of advanced hybrid electric aircraft. The award follows the successful completion of multiple programs where KTT completed concept and engine trade studies for Group 3 UAVs with the guided leadership of AFRL/RQT. The objective of the awarded task order is to complete the engine development for flight testing and to demonstrate the high-power-to-weight, high-efficiency, and increased durability of the recuperated engine design. Work will be performed by KTT in 
Florida.

Stacey Rock, President of Kratos Turbine Technologies Division, said, “The recent award demonstrates KTT’s commitment to developing high-performing and affordable engines for the warfighter. All of Kratos is focused on supporting 
the United States warfighter and industrial base, including making significant investments in the development and production of next generation engines and supporting STEM opportunities in the 
USA. We look forward to continuing to support AFRL in the development of transformative and affordable turbine engine technologies.”

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
[email protected]

Source: Kratos Defense & Security Solutions, Inc.

Harte Hanks Promotes Brian Linscott to Chief Executive Officer


Harte Hanks Promotes Brian Linscott to Chief Executive Officer

 

Linscott’s Two-year Plus Company Senior Executive Role Ensures Continuity of Experienced Leadership

 

AUSTIN, Texas
June 23, 2021 /PRNewswire/ — 
Harte Hanks, Inc. (OTCQX: HRTH), an industry leader 
in Marketing Services and Execution, Customer Care, Fulfillment and Logistics Services, today announced that its Board of Directors has promoted Chief Operating Officer Brian Linscott to the position of CEO, succeeding Andrew Benett, effective immediately.

Mr. Benett is stepping down from his role as Chief Executive Officer to pursue other opportunities after positioning 
Harte Hanks for ongoing success.  Mr. Linscott and  Mr. Benett have agreed to work together to ensure a smooth transition at the Company.

Jack Griffin, Chairman of the Board of 
Harte Hanks, stated, ” Mr. Benett and  Mr. Linscott have worked closely together over the past 18 months and this transition ensures continuity of seasoned leadership at Harte Hanks. Brian’s success at 
Harte Hanks and his two plus decades of experience in operations, growth strategies, acquisitions, and finance, as well as leading teams in the development of new client opportunities positions Brian perfectly to lead Harte Hanks as our new CEO in our next phase of profitable growth.”

Mr. Linscott added, “We have worked to structure Harte Hanks for growth and profitability as our clients get back to business. I am honored to lead 
Harte Hanks’ outstanding team at this exciting time as we enter the next phases of this post-pandemic world.”

Brian has an accomplished track record for improving financial and operational results. Before joining 
Harte Hanks in late 2019, his prior positions include CFO of 
Sun Times Media, LLC, a media company that included the Chicago Sun-Times, Managing Director of Huron Consulting Group, and a Partner at 
BR Advisors, where he led operational improvements, developed new partnerships and drove topline growth for media clients and other companies.

Mr. Griffin continued, “I want to thank Andrew for his hard work and dedication in leading the Company through the challenges of restructuring our organization during the COVID-19 pandemic as well as maintaining the confidence and loyalty of our clients.”  

“I am proud of the progress we have achieved at 
Harte Hanks, and it has been a pleasure building and leading such a strong team,” said  Andrew Benett. “Brian is an accomplished corporate executive, and I am confident that he has the skills to lead execution at 
Harte Hanks going forward.”

About Harte Hanks 

Harte Hanks is a global marketing services firm specializing in customer lifecycle management.  
Harte Hanks effectively connects our clients with their customers in powerful ways. We are experts in defining, executing and optimizing the customer journey by offering end-to-end BPO marketing services including lead generation, data analytics, and multi-channel customer engagement solutions (digital, social, and mobile), as well as contact center, fulfillment and logistics services. From visionary thinking to tactical execution, Harte Hanks delivers smarter customer interactions for some of the world’s leading brands. Harte Hanks has approximately 2,500 employees located in North America, Asia-Pacific and Europe.

Cautionary Note Regarding Forward-Looking Statements:

Our press release and related earnings conference call contain “forward-looking statements” within the meaning of 
U.S. federal securities laws. All such statements are qualified by this cautionary note, provided pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Statements other than historical facts are forward-looking and may be identified by words such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “seeks,” “could,” “intends,” or words of similar meaning.  These forward-looking statements are based on current information, expectations and estimates and involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.  In that event, our business, financial condition, results of operations or liquidity could be materially adversely affected and investors in our securities could lose part or all of their investments.  These risks, uncertainties, assumptions and other factors include: (a) local, national and international economic and business conditions, including (i) the outbreak of diseases, such as the COVID-19 coronavirus, which has curtailed travel to and from certain countries and geographic regions, disrupted business operations resulting from travel restrictions and reduced consumer spending, and uncertainty regarding the duration of the virus’ impact, (ii) market conditions that may adversely impact marketing expenditures and (iii) the impact of economic environments and competitive pressures on the financial condition, marketing expenditures and activities of our clients and prospects; (b) the demand for our products and services by clients and prospective clients, including (i) the willingness of existing clients to maintain or increase their spending on products and services that are or remain profitable for us, and (ii) our ability to predict changes in client needs and preferences; (c) economic and other business factors that impact the industry verticals we serve, including competition and consolidation of current and prospective clients, vendors and partners in these verticals; (d) our ability to manage and timely adjust our facilities, capacity, workforce and cost structure to effectively serve our clients; (e) our ability to improve our processes and to provide new products and services in a timely and cost-effective manner though development, license, partnership or acquisition; (f) our ability to protect our facilities against security breaches and other interruptions and to protect sensitive personal information of our clients and their customers; (g) our ability to respond to increasing concern, regulation and legal action over consumer privacy issues, including changing requirements for collection, processing and use of information; (h) the impact of privacy and other regulations, including restrictions on unsolicited marketing communications and other consumer protection laws; (i) fluctuations in fuel prices, paper prices, postal rates and postal delivery schedules; (j) the number of shares, if any, that we may repurchase in connection with our repurchase program; (k) unanticipated developments regarding litigation or other contingent liabilities; (l) our ability to complete anticipated divestitures and reorganizations, including cost-saving initiatives; (m) our ability to realize the expected tax refunds; and (n) other factors discussed from time to time in our filings with the 
Securities and Exchange Commission, including under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended 
December 31, 2020 which was filed on 
March 24, 2021. The forward-looking statements in this press release are made only as of the date hereof, and we undertake no obligation to update publicly any forward-looking statement, even if new information becomes available or other events occur in the future.

Contact: For more information, visit 
Harte Hanks at www.hartehanks.com, call 800-456-9748, or email us at [email protected] and/ or [email protected].

SOURCE: 
Harte Hanks

Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso®


Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

 

AUSTIN, Texas — (June 23, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and confirmed all comments have been addressed regarding the Company’s clinical trial protocol for the Acclaim-1 clinical trial, an open-label, multi-center Phase 1/2 clinical trial evaluating the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with AstraZeneca’s Tagrisso® in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso. In January 2020, Genprex received FDA Fast Track Designation for the Acclaim-1 patient population.

In addition, the Company has engaged its first clinical site for Acclaim-1, and Genprex is continuing to work with a number of other important cancer research centers and academic institutions to select optimal study sites.

“This feedback from the FDA on our Acclaim-1 clinical trial and the engagement of our first clinical site are key milestones for Genprex,” said Rodney Varner, President and Chief Executive Officer of Genprex. “We are now looking forward to opening patient enrollment in this important study of this cutting-edge investigational gene therapy to evaluate the role it can play in the fight against lung cancer, the leading cause of cancer deaths worldwide.”

The Company expects the Phase 1 portion of the Acclaim-1 trial to enroll up to 18 patients at three clinical sites and for the Phase 2 portion to enroll approximately 74 patients (a 1:1 ratio of REQORSA and Tagrisso combination therapy versus Tagrisso monotherapy) at up to 15 clinical sites. The first part of the Phase 1/2 clinical trial will be a dose escalation study. The primary endpoint of the Phase 2 portion of the trial is progression-free survival, which is defined as time from randomization after first progression on Tagrisso, to first event (second progression) or death. An interim analysis will be performed at 51 events.

Genprex recently announced the Centralized Institutional Review Board (IRB) approval for the Acclaim-1 clinical trial in NSCLC. Additional information about the Acclaim-1 clinical trial can be found by visiting ClinicalTrials.gov.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform for cancer. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso.

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

Media Contact

Genprex Media Relations

Kalyn Dabbs

(877) 774-GNPX (4679) ext. #3

C-Suite Interview with CoreCivic (CXW) President & CEO Damon Hininger


Noble Capital Markets Senior Research Analyst Joe Gomes sits down with CoreCivic President & CEO Damon Hininger for this exclusive interview.

Research, News, and Advanced Market Data on CXW


View all C-Suite Interviews

About CoreCivic

CoreCivic is a diversified government solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. CoreCivic provides a broad range of solutions to government partners that serve the public good through corrections and detention management, a network of residential reentry centers to help address America’s recidivism crisis, and government real estate solutions. CoreCivic is the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believes it is the largest private owner of real estate used by government agencies in the U.S. CoreCivic has been a flexible and dependable partner for government for more than 35 years. CoreCivic’s employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good.

Virtual Roadshow with Helius Medical Technologies (HSDT) Interim CEO, CFO/COO, and Medical Advisor


Helius Medical Technologies Interim CEO Dane Andreeff, CFO/COO Joyce LaViscount, and Medical Advisor Jonathan Sackier make a formal corporate presentation. Afterwards, they are joined by Noble Capital Markets Senior Research Analyst Joe Gomes for a Q & A session featuring questions asked by the live audience throughout the event.

Research, News, and Advanced Market Data on HSDT


Information on upcoming live virtual roadshows

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.

Investment Opportunities in Hydrogen



Unhyped Hydrogen Investments

 

Hydrogen finally seems on the road to fulfilling its “promise” of becoming a large contributor to the renewable energy mosaic. The interest in hydrogen energy was reignited last year with the push toward zero carbon emissions. Some other drivers of this elevated interest are increased government support and public interest in clean energy options. Hydrogen has been spoken about since the ’70s gas crisis as being the “answer.” It appears as though when it comes to lower emissions, power storage, and abundance, hydrogen is a prime candidate to be part of the answer.

There are many applications for hydrogen and hydrogen fuel cells, and as with most renewable energy solutions, there is some level of “baggage” that comes with each. We’ll discuss the baggage alongside the applications and provide the names of investable companies operating in and with the potential to benefit from the growth of hydrogen as a power source.

 

Powerful Applications for H

Processing Chemicals – Hydrogen’s primary use today is as a catalyst or agent in chemical and industrial processes. Among the chemical processes is the production of methanol and ammonia. The ammonia produced is used directly or indirectly as fertilizer. Hydrogen is also used to refine oil and as part of a process to remove impurities from crude oil. In steel production, it can be used to replace the traditional fuel (cokes) in a blast furnace. These processes are all currently being used and largely executed by what is called “dirty” or “grey” hydrogen.

 Automotive Fuel Cell– At the turn of the Millenium, hydrogen was going to be the clean-energy answer.   President George W. Bush even brought it up in his 2003 State of the Union address, saying, “the first car driven by a child born today could be powered by hydrogen and pollution-free.

The unfilled expectations around hydrogen to power transportation have their reasons.  From a practical standpoint using a driver’s perspective, the shift would seem easy.  Fuelling a car with liquid H takes a similar amount of time as refilling with gas or diesel; the driving range would also be about the same. One issue preventing widespread use is the infrastructure for hydrogen refueling is not in place. And, as we have seen with electric vehicles, one can’t sell alternative “fuel” cars without the ability to fuel them along the road. On the other hand, building fuel stations isn’t economically feasible until there are customers. The solution to this chicken/egg question has yet to avail itself.

Heavy-Duty Transport– This category is comprised mainly of trains and boats. Hydrogen is a high-density energy source that can provide the appropriate power for heavy goods vehicles. It can provide power where we now implement diesel. Hydrogen is quick to refuel, which reduces downtime in these applications.

Forklifts– Fuel cells are already widely used in forklift fleets. One big advantage of hydrogen-powered fuel cells is it saves time compared to battery-powered machines. The benefits are particularly strong in a three-shift, round-the-clock operation. Fuel cells powered by hydrogen are also without carbon monoxide, which is preferable indoors. Large warehouses operated by Amazon and Walmart use hydrogen-powered forklift fleets.

Power Plants– Stationary Power plants are also using hydrogen fuel cells. They can be used as primary and backup power. The power is reliable and can support on-grid or off-grid power generation. These stationary fuel cells are able to connect directly to the gas infrastructure.

 

Grey Hydrogen vs. Green Hydrogen, What’s the Difference?

Hydrogen is as clean as the production method. Most hydrogen currently produced is called “dirty” or “grey” hydrogen. This means it was produced from natural gas and emits greenhouse gas. Grey hydrogen is produced using a process that isn’t the super clean hydrogen envisioned 20 or more years ago. That hydrogen, the one that emits no greenhouse gases, is referred to as “green” hydrogen. The difference provides a challenge and investment opportunities for this emerging field.  There is a lot of grey hydrogen used today that can be replaced by green hydrogen. It is estimated more than 95% of hydrogen production in 2019 was grey. Converting one to the other isn’t without cost, but it is then truly green.

Hydrogen can be produced using another method that is somewhat cleaner than grey. It uses natural gas and is called steam reforming. With steam reforming, it’s possible to capture 80% to 90% of the CO2 produced in the process. This CO2 is then used in other processes. You’ll hear hydrogen separated in this way called “blue” hydrogen. An alternative natural gas technique that doesn’t generate CO2 creates “turquoise” hydrogen.

 

Investments In Hydrogen

 There are many companies worldwide in this space.  The largest companies are hydrogen producers, which mainly use the method of steam reforming. Smaller niche companies focus on specific aspects of hydrogen. These can be sub-categorized into electrolyzer producers and fuel cell producers. Some companies will combine the two providing a fully integrated hydrogen producer.

There is a movement toward green hydrogen for most involved. This movement includes joint ventures, sometimes the small helping the big. Linde (LIN), for example, has a joint venture with ITM Power (OTCPK:ITMPF). ITM Linde Electrolysis provides industrial-scale turnkey solutions for green hydrogen production.

 

Electrolyzers

Electrolyzers are one way to invest in green hydrogen. There is a lot of wind, and solar-produced energy coming onto the power grid. One problem with this is the unstable production associated with these methods. By transforming this energy into green hydrogen, it can replace the current supply of grey hydrogen. electrolyzers may be the best way to invest in hydrogen.

Electrolyzers use a system that, with the use of electricity, breakdown water (H2O) into hydrogen and oxygen in a process known as electrolysis. McPhy Energy SA (OTC:MPHYF) is a designer, manufacturer, and integrator of hydrogen equipment. Its product range features two main categories: Electrolyzers (hydrogen production equipment) of all capacities and hydrogen refueling stations (refueling/distribution equipment) for hydrogen-powered mobility. Another company, Nel Hydrogen (NLLSY) covers the entire chain from hydrogen production to the manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with fast fueling similar to conventional vehicles. The company’s segments include Fueling and Electrolyzer. ITM Power PLC (ITMPF) designs and manufactures integrated hydrogen energy systems for energy storage and clean fuel production.

The above companies are European with valuations that may cause concern in other industries. They are listed because they are pure-plays on green hydrogen and electrolysis.

SunHydrogen (OTCPK:
HYSR) could become an alternative to electrolyzer companies. SunHydrogen is working on an innovative hydrogen generator. The generator uses solar energy to split water into hydrogen and oxygen directly. The technology is still in the design and test stage.

 

Fuel Cell Companies

Fuel cells are necessary to convert hydrogen into electricity. They can be used in transportation or stationary power systems. Fuel cells can also be powered by other fuels such as natural gas. Most companies are focusing on fuel cells powered with hydrogen or flexible fuel cells. Ballard Power Systems (Nasdaq:BLDP) designs, develops, manufactures, sells, and services fuel cell products for a variety of applications, focusing on motive power (material handling and buses) and stationary power (backup power, supplemental power, and distributed generation). Fuel Cell Energy ((Nasdaq:FCEL) designs manufactures, sells, installs, operates, and services fuel-cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as wastewater treatment, commercial and hospitality, data centers and communications, education and healthcare, and others. Plug Power (Nasdaq:PLUG) just announced their plans to build a plant to create green hydrogen. The plant will produce 15 tons per day of liquid green hydrogen, produced using 100% renewable energy and intended to fuel transportation applications, including material handling and fuel cell electric vehicle fleets. Plug Power is investing $84 million in the facility, which is expected to create at least 24 jobs in the local community starting in 2022. Plug is an innovator of green hydrogen and fuel cell technology.

 

Conclusion

Wind, solar, nuclear, and other Renewables are getting investors’ attention. Hydrogen has been spoken about for decades, but like electric vehicles, technology had to catch up with the desire to benefit from the potential. Globally, a move toward renewables is being supported by the major economies, closing the gap on the needed technology is now happening and ramp speed.

 

Suggested Reading:

How Does the Gates Buffett Natrium Reactor Works?

Is the Future of Nuclear, Small Modular Reactors?



What Companies are Involved in Spaceflight?

The Future of Electric Vehicles

 

Sources:

https://www.fchea.org/stationary

https://safety4sea.com/seven-energy-and-maritime-companies-collaborate-on-hydrogen/

https://www.iea.org/data-and-statistics/data-products

https://www.iea.org/fuels-and-technologies/hydrogen

 

Stay up to date. Follow us:

           


Stay up to date. Follow us:

QuickChek – June 23, 2021



Esports Entertainment Group Named Official Esports Tournament Provider of the New York Rangers

The New York Rangers announced a marketing partnership with Esports Entertainment Group Inc. (EEG), naming the esports company their Official esports tournament provider, beginning on July 1

Research, News & Market Data on Esports Entertainment Group

Watch recent presentation from EEG



Harte Hanks Promotes Brian Linscott to Chief Executive Officer

Harte Hanks, Inc. announced that its Board of Directors has promoted Chief Operating Officer Brian Linscott to the position of CEO, succeeding Andrew Benett, effective immediately

Research, News & Market Data on Harte Hanks



Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

Genprex announced that the U.S. Food and Drug Administration (FDA) has reviewed and confirmed all comments have been addressed regarding the Company’s clinical trial protocol for the Acclaim-1 clinical trial

Research, News & Market Data on Genprex

Watch recent presentation from Genprex



Capstone Green Energy Secures Three New Rentals And Announces Expansion Of Its Rental Fleet, From 10.6 MW To 12.1 MW

Capstone Green Energy announced that it continues to expand its long-term microturbine rental business as part of its growing Energy as a Service (EaaS) business model

Research, News & Market Data on Capstone Green Energy

Watch recent presentation from Capstone Green Energy



Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

Cocrystal Pharma announced the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A

Research, News & Market Data on Cocrystal Pharma

Watch recent presentation from Cocrystal Pharma



electroCore, Inc. Announces Exclusive Distribution Agreement with Kromax For Taiwan and China

electroCore, Inc. announced it has entered into an agreement with Kromax International Corporation to serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator in Taiwan and China

Research, News & Market Data on electroCore

Stay up to date. Follow us:

Release – Genprex Announces Initiation of its Phase 1 2 Acclaim-1 Clinical Trial for REQORSA Immunogene Therapy


Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review

 

AUSTIN, Texas — (June 23, 2021) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and confirmed all comments have been addressed regarding the Company’s clinical trial protocol for the Acclaim-1 clinical trial, an open-label, multi-center Phase 1/2 clinical trial evaluating the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with AstraZeneca’s Tagrisso® in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso. In January 2020, Genprex received FDA Fast Track Designation for the Acclaim-1 patient population.

In addition, the Company has engaged its first clinical site for Acclaim-1, and Genprex is continuing to work with a number of other important cancer research centers and academic institutions to select optimal study sites.

“This feedback from the FDA on our Acclaim-1 clinical trial and the engagement of our first clinical site are key milestones for Genprex,” said Rodney Varner, President and Chief Executive Officer of Genprex. “We are now looking forward to opening patient enrollment in this important study of this cutting-edge investigational gene therapy to evaluate the role it can play in the fight against lung cancer, the leading cause of cancer deaths worldwide.”

The Company expects the Phase 1 portion of the Acclaim-1 trial to enroll up to 18 patients at three clinical sites and for the Phase 2 portion to enroll approximately 74 patients (a 1:1 ratio of REQORSA and Tagrisso combination therapy versus Tagrisso monotherapy) at up to 15 clinical sites. The first part of the Phase 1/2 clinical trial will be a dose escalation study. The primary endpoint of the Phase 2 portion of the trial is progression-free survival, which is defined as time from randomization after first progression on Tagrisso, to first event (second progression) or death. An interim analysis will be performed at 51 events.

Genprex recently announced the Centralized Institutional Review Board (IRB) approval for the Acclaim-1 clinical trial in NSCLC. Additional information about the Acclaim-1 clinical trial can be found by visiting ClinicalTrials.gov.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform for cancer. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is then administered intravenously, where it is then taken up by tumor cells that express proteins that are deficient. The Company’s lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with AstraZeneca’s Tagrisso® (osimertinib) for patients with EFGR mutations whose tumors progressed after treatment with Tagrisso.

For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex’s reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under “Item 1A – Risk Factors” in Genprex’s Annual Report on Form 10-K.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex’s clinical trials and regulatory approvals; the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes;  Genprex’s future growth and financial status; Genprex’s commercial and strategic partnerships including the scale up of the manufacture of its product candidates; and Genprex’s intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.

(877) 774-GNPX (4679)

Investor Relations

GNPX Investor Relations

(877) 774-GNPX (4679) ext. #2

Media Contact

Genprex Media Relations

Kalyn Dabbs

(877) 774-GNPX (4679) ext. #3

Release – Harte Hanks Promotes Brian Linscott to Chief Executive Officer


Harte Hanks Promotes Brian Linscott to Chief Executive Officer

 

Linscott’s Two-year Plus Company Senior Executive Role Ensures Continuity of Experienced Leadership

 

AUSTIN, Texas
June 23, 2021 /PRNewswire/ — 
Harte Hanks, Inc. (OTCQX: HRTH), an industry leader 
in Marketing Services and Execution, Customer Care, Fulfillment and Logistics Services, today announced that its Board of Directors has promoted Chief Operating Officer Brian Linscott to the position of CEO, succeeding Andrew Benett, effective immediately.

Mr. Benett is stepping down from his role as Chief Executive Officer to pursue other opportunities after positioning 
Harte Hanks for ongoing success.  Mr. Linscott and  Mr. Benett have agreed to work together to ensure a smooth transition at the Company.

Jack Griffin, Chairman of the Board of 
Harte Hanks, stated, ” Mr. Benett and  Mr. Linscott have worked closely together over the past 18 months and this transition ensures continuity of seasoned leadership at Harte Hanks. Brian’s success at 
Harte Hanks and his two plus decades of experience in operations, growth strategies, acquisitions, and finance, as well as leading teams in the development of new client opportunities positions Brian perfectly to lead Harte Hanks as our new CEO in our next phase of profitable growth.”

Mr. Linscott added, “We have worked to structure Harte Hanks for growth and profitability as our clients get back to business. I am honored to lead 
Harte Hanks’ outstanding team at this exciting time as we enter the next phases of this post-pandemic world.”

Brian has an accomplished track record for improving financial and operational results. Before joining 
Harte Hanks in late 2019, his prior positions include CFO of 
Sun Times Media, LLC, a media company that included the Chicago Sun-Times, Managing Director of Huron Consulting Group, and a Partner at 
BR Advisors, where he led operational improvements, developed new partnerships and drove topline growth for media clients and other companies.

Mr. Griffin continued, “I want to thank Andrew for his hard work and dedication in leading the Company through the challenges of restructuring our organization during the COVID-19 pandemic as well as maintaining the confidence and loyalty of our clients.”  

“I am proud of the progress we have achieved at 
Harte Hanks, and it has been a pleasure building and leading such a strong team,” said  Andrew Benett. “Brian is an accomplished corporate executive, and I am confident that he has the skills to lead execution at 
Harte Hanks going forward.”

About Harte Hanks 

Harte Hanks is a global marketing services firm specializing in customer lifecycle management.  
Harte Hanks effectively connects our clients with their customers in powerful ways. We are experts in defining, executing and optimizing the customer journey by offering end-to-end BPO marketing services including lead generation, data analytics, and multi-channel customer engagement solutions (digital, social, and mobile), as well as contact center, fulfillment and logistics services. From visionary thinking to tactical execution, Harte Hanks delivers smarter customer interactions for some of the world’s leading brands. Harte Hanks has approximately 2,500 employees located in North America, Asia-Pacific and Europe.

Cautionary Note Regarding Forward-Looking Statements:

Our press release and related earnings conference call contain “forward-looking statements” within the meaning of 
U.S. federal securities laws. All such statements are qualified by this cautionary note, provided pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Statements other than historical facts are forward-looking and may be identified by words such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “seeks,” “could,” “intends,” or words of similar meaning.  These forward-looking statements are based on current information, expectations and estimates and involve risks, uncertainties, assumptions and other factors that are difficult to predict and that could cause actual results to vary materially from what is expressed in or indicated by the forward-looking statements.  In that event, our business, financial condition, results of operations or liquidity could be materially adversely affected and investors in our securities could lose part or all of their investments.  These risks, uncertainties, assumptions and other factors include: (a) local, national and international economic and business conditions, including (i) the outbreak of diseases, such as the COVID-19 coronavirus, which has curtailed travel to and from certain countries and geographic regions, disrupted business operations resulting from travel restrictions and reduced consumer spending, and uncertainty regarding the duration of the virus’ impact, (ii) market conditions that may adversely impact marketing expenditures and (iii) the impact of economic environments and competitive pressures on the financial condition, marketing expenditures and activities of our clients and prospects; (b) the demand for our products and services by clients and prospective clients, including (i) the willingness of existing clients to maintain or increase their spending on products and services that are or remain profitable for us, and (ii) our ability to predict changes in client needs and preferences; (c) economic and other business factors that impact the industry verticals we serve, including competition and consolidation of current and prospective clients, vendors and partners in these verticals; (d) our ability to manage and timely adjust our facilities, capacity, workforce and cost structure to effectively serve our clients; (e) our ability to improve our processes and to provide new products and services in a timely and cost-effective manner though development, license, partnership or acquisition; (f) our ability to protect our facilities against security breaches and other interruptions and to protect sensitive personal information of our clients and their customers; (g) our ability to respond to increasing concern, regulation and legal action over consumer privacy issues, including changing requirements for collection, processing and use of information; (h) the impact of privacy and other regulations, including restrictions on unsolicited marketing communications and other consumer protection laws; (i) fluctuations in fuel prices, paper prices, postal rates and postal delivery schedules; (j) the number of shares, if any, that we may repurchase in connection with our repurchase program; (k) unanticipated developments regarding litigation or other contingent liabilities; (l) our ability to complete anticipated divestitures and reorganizations, including cost-saving initiatives; (m) our ability to realize the expected tax refunds; and (n) other factors discussed from time to time in our filings with the 
Securities and Exchange Commission, including under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended 
December 31, 2020 which was filed on 
March 24, 2021. The forward-looking statements in this press release are made only as of the date hereof, and we undertake no obligation to update publicly any forward-looking statement, even if new information becomes available or other events occur in the future.

Contact: For more information, visit 
Harte Hanks at www.hartehanks.com, call 800-456-9748, or email us at [email protected] and/ or [email protected].

SOURCE: 
Harte Hanks

Release – Capstone Green Energy Secures Three New Rentals And Announces Expansion Of Its Rental Fleet

 


Capstone Green Energy (Nasdaq:Cgrn) Secures Three New Rentals And Announces Expansion Of Its Rental Fleet, From 10.6 MW To 12.1 MW

 

Rented by an Oil & Gas Producer, Industrial Agricultural and Industrial Plastic Company

VAN NUYS, CA / ACCESSWIRE / June 23, 2021 / Capstone Green Energy Corporation(www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) formerly Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) (“Capstone” or the “Company”), announced today that it continues to expand its long-term microturbine rental business as part of its growing Energy as a Service (EaaS) business model, with an additional 1.1 megawatt (MW) of new long-term rental contracts. As a result, Capstone also announced today that it has expanded its low emission microturbine rental fleet from 10.6 MW to 12.1 MW.

The first of the new long-term rental contracts is a five-year rental agreement for a new C200 Signature Series slated for a local independent oil and gas producer focused on mature field revitalization, acquisitions, and exploration. The company optimizes and develops existing and acquired assets, and also implements thermal enhanced oil recovery and other technologies to expand existing oil production. This contract was secured by Capstone’s local distribution partner, Cal Microturbine, Capstone’s exclusive distributor for California, Hawaii, and Nevada and nonexclusive for Oregon and Washington (www.calmicroturbine.com).

The second long-term rental contract is a minimum five-month rental contract for a C800S for a new industrial agricultural operation. This rental agreement was secured by Capstone’s new Direct Solutions Sales organization. The five-month rental was pre-paid and was commissioned in mid-June.

The third rental contract is a one-year rental of a C65 for an industrial plastic company looking to utilize waste gas from a plastic recycling process. “If the C65 rental system operates satisfactorily on this off-spec gas, the customer has additional gas it’s not using at multiple other locations,” stated Jim Crouse, Capstone Green Energy, Chief Revenue Officer. “The rental program offers a unique and efficient method to test customer’s off-spec fuels that will allow us to determine applicability and durability in a fraction of the time it’s taken us in the past,” added Mr. Crouse.

Like Capstone Green Energy, all three customers are committed to health, safety, and environmental excellence. Leveraging Capstone Green Energy’s innovative microturbine technology will help all three companies save money and reduce their carbon footprint.

“Expanding Capstone’s Energy as a Service business, which includes the long-term rental program, is an important element for the Company achieving its strategic goals. Capstone is an eminent green energy company, having focused for a long time on transforming the way businesses think about on-site energy production,” said Darren Jamison, President and Chief Executive Officer of Capstone Green Energy.

“Growing our rental fleet is a key part of the business plan that we developed in conjunction with amending the Goldman Sachs Note Purchase Agreement on October 1, 2020, which includes the strategic expansion of the long-term rental fleet from 8.6 MW to 21.1 MW by March 2022,” said Eric Hencken, Chief Financial Officer of Capstone Green Energy. “Long-term rentals are a key to our future financial success as the recurring revenue stream they generate improves our gross margin and expense absorption,” concluded Mr. Hencken.

About Capstone Green Energy

Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Conversion Products are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Products business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen Energy Solutions, Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: [email protected]. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three years are estimated at 1,115,100 tons of carbon and $698 million in annual energy savings.

For more information about the Company, please visit: www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on TwitterLinkedInInstagramFacebook, and YouTube.

Cautionary Note Regarding Forward-Looking Statements

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:
Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
[email protected]

SOURCE: Capstone Green Energy

Release – electroCore Inc. Announces Exclusive Distribution Agreement with Kromax For Taiwan and China


electroCore, Inc. Announces Exclusive Distribution Agreement with Kromax For Taiwan and China

 

ROCKAWAY, NJ
June 23, 2021 (GLOBE NEWSWIRE) — 
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced it has entered into an agreement with Kromax International Corporation to serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in 
Taiwan and 
China.

“Kromax International Corp. is dedicated to transforming healthcare quality by introducing state-of-art medical solutions that improve the health of patients,” commented  Tim Hwang
Kromax Group Vice Chairman. “We have been deeply involved in the field of pain management and neuromodulation in the 
Taiwan
China, and 
South Asia markets for many years and are honored to cooperate with electroCore by representing their solution in these markets, providing benefits to patients in our region suffering from migraines.”

“We are delighted to partner with Kromax to introduce gammaCore into 
Taiwan and China,” stated Iain Strickland, electroCore’s Vice President of Global Sales and Strategy. “Kromax and electroCore share the common goal of utilizing proven healthcare innovations to improve the health and lives of their patients. We look forward to collaborating with the team at Kromax to help support the adoption of gammaCore in the region.”

The initial term of the agreement is three years, and it contains customary terms and conditions. Regulatory clearances are required before sales and revenue can occur, and the timing for any such potential clearances is uncertain at this time.

        
About Kromax

Founded in 1987, Kromax provides services covering the semiconductor, LCD, LED, solar and biotech industries in the 
Greater China area. Their business philosophy focuses on providing comprehensive services to the customer, starting from the early stages of research and marketing and also touching sales, production, distribution, installation, and warranty support. Their mission is to continually enhance the ability of our customers to compete in the international marketplace by bringing them the latest, most advanced technology.

For more information, visit www.kromax.com/en-US/AboutKromax.aspx

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are for the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCoreTM

gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, and the acute and preventive treatment of migraine in adolescent (ages 12 and older) and adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

  • gammaCore is contraindicated for patients if they:
    • Have an active implantable medical device, such as pacemaker, hearing aid implant, or implanted electronic device
    • Have a metallic device such as a stent, bone plate, or bone screw, implanted at or near the neck
    • Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)
  • Safety and efficacy of gammaCore have not been evaluated in the following patients:
    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric patients (less than 12 years of age)
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia

Please refer to the gammaCore Instructions for Use for all the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the Company’s business prospects in 
Taiwan
China, and other new markets and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the 
SEC available at www.sec.gov.

Investors:
Rich CockrellCG Capital
404-736-3838
[email protected]

or

Media Contact:
Summer Diaz
electroCore
816-401-6333
[email protected]

Release – Esports Entertainment Group Named Official Esports Tournament Provider of the New York Rangers

 


Esports Entertainment Group Named Official Esports Tournament Provider of the New York Rangers

 

Esports Gaming League will Host Three Rangers-Themed Esports Tournaments

NEW YORK–()–The New York Rangers announced today a marketing partnership with Esports Entertainment Group Inc. (EEG), naming the esports company their Official esports tournament provider, beginning on July 1. As part of this relationship, EEG will operate three Rangers-themed esports tournaments utilizing its Esports Gaming League brand and platform. EEG will work with the Rangers organization to create custom videos that promote these tournaments across all Rangers digital platforms. Each tournament will include incredible prizes such as Rangers merchandise and memorabilia.

“Over the last few years, we’ve hosted dozens of amateur esports tournaments with our esports organization CLG, which have been incredibly well received and we can’t wait to expand on this with the Rangers,” said Dan Fleeter, Vice President, Business Operations, MSG Sports Corp. “We look forward to a long and mutually rewarding relationship with EEG and believe this is a wonderful opportunity to engage with an audience interested in hockey and gaming.”

Esports Gaming League enables live and online events and tournaments where gamers can compete and enjoy a wide range of content relating to esports and video games on a proprietary technology platform. Services include full turnkey esports events, live broadcast production, game launches, and online branded tournaments.

“We are thrilled to welcome another leading professional sports team to our tournament platform,” said Grant Johnson, CEO of Esports Entertainment Group. “We look forward to working with the Rangers as they extend their brand into the rapidly growing world of esports.”

“We are quickly becoming the industry standard tournament platform for professional sports, as teams recognize the strength of our platform and its ability to meet the demanding needs of large-scale deployments,” said Magnus Leppäniemi, President of Esports at Esports Entertainment Group. “We look forward to helping the Rangers achieve their goals in this exciting new arena.”

Madison Square Garden Sports Corp.

Madison Square Garden Sports Corp. (MSG Sports) is a leading professional sports company, with a collection of assets that includes: the New York Knicks (NBA) and the New York Rangers (NHL); two development league teams – the Westchester Knicks (NBAGL) and the Hartford Wolf Pack (AHL); and esports teams through Counter Logic Gaming, a leading North American esports organization, and Knicks Gaming, an NBA 2K League franchise. MSG Sports also operates two professional sports team performance centers – the MSG Training Center in Greenburgh, NY and the CLG Performance Center in Los Angeles, CA. More information is available at www.msgsports.com.

About Esports Entertainment Group

Esports Entertainment Group, Inc. is an esports and iGaming company. The Company maintains offices in New Jersey, the UK and Malta. For more information, visit: www.esportsentertainmentgroup.com

Contacts

MEDIA CONTACTS:
Madison Square Garden Sports:
[email protected]

Esports Entertainment Group:
[email protected]